The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study

BACKGROUND: Patients with type 2 diabetes present with an accelerated atherosclerotic process. Animal evidence indicates that dipeptidyl peptidase-4 inhibitors (gliptins) have anti-inflammatory and anti-atherosclerotic effects, yet clinical data are scarcely available. DESIGN AND METHODS: A prospect...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cardiovasc Diabetol
Glavni autori: Younis, Arwa, Eskenazi, Dana, Goldkorn, Ronen, Leor, Jonathan, Naftali-Shani, Nili, Fisman, Enrique Z., Tenenbaum, Alexander, Goldenberg, Ilan, Klempfner, Robert
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2017
Teme:
Original Investigation
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5440983/
https://ncbi.nlm.nih.gov/pubmed/28532406
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-017-0551-5
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items